Clinical Trials Directory

Trials / Completed

CompletedNCT05819710

A Study to Investigate the Next-day Residual Effects of TS-142 in Healthy Elderly Subjects

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
43 (actual)
Sponsor
Taisho Pharmaceutical Co., Ltd. · Industry
Sex
All
Age
65 Years
Healthy volunteers
Accepted

Summary

This is a study to investigate the next-day residual effects of a single bedtime dosing of 5 mg and 10 mg of TS-142 in Japanese healthy elderly participants in double-blind manner.

Conditions

Interventions

TypeNameDescription
DRUGTS-142Single dose of 5 mg of TS-142
DRUGTS-142Single-dose of 10 mg of TS-142
DRUGZopicloneSingle-dose of 7.5 mg of zopiclone
DRUGPlaceboSingle-dose of placebo

Timeline

Start date
2023-05-15
Primary completion
2023-08-25
Completion
2023-08-25
First posted
2023-04-19
Last updated
2025-02-28

Locations

1 site across 1 country: Japan

Source: ClinicalTrials.gov record NCT05819710. Inclusion in this directory is not an endorsement.